Epidermal growth factor (EGF) in pharmacologic doses is able to induce growth and development in the fetus and the newborn. To investigate the opposite situation, the effects of insufficient amounts of EGF during development, we wanted to establish an in vivo model with a state of EGF deficiency. This was attempted by induction of autoimmunity to EGF in rats. Twenty rats were immunized with EGF. Fifteen of these developed autoantibodies against EGF, which, as judged by Scatchard analysis, had a median apparent affi nity constant of 14 X 10 9 L Imol and a median concentration of binding sites of 20 X 10-9 mol/L, The antibodies recognized purified EGF from the submandibular glands (6 kD) and from urine (45 kD) and further native EGF in saliva and urine. The cross-reactivity toward transforming growth factor-a was below 3%. Binding of EGF by antibodies inhibited its binding to the EGF-receptor by approximately 97% in vitro. Investigation of in vivo metabolism of EGF is a 53-amino acid peptide, discovered by Stanley Cohen (1), wit h an ability to accelerate ey elid opening and incisor eruption in newborn mice . Its human counterpart w as iso lat ed from urine and initially named urogastrone, be cause it co uld inhibit gastric acid sec retio n (2) . Today it is known th at EGF is produced in several organ s, including the submandibul ar glands, the respiratory sys tem , th e kidneys, and the digestiv e tract (3, 4). Its receptor has been identified in most organs stud ied (5) . EGF is abl e to induce g row th and differentiation, antibody-bound 125I_EGF confirmed these results, that is, the antibodies were able to inactivate EGF. The adult rats were unaffected by the induction and presence of autoantibodies, and the EGF-containing organs did not show any histologic signs of inflammation or tissue damage. Furthermore, as judged by immunohistochemistry, no major changes in the distribution and tissue concentration of EGF were seen in the adult rat. These results show that it is possible to induce homologous antibodies that can inhibit the binding of EGF to its receptor and further suggest that circulatory EGF is of no physiologic importance in the healthy, adult rat. (Pediatr Res 37: 169-174, 1995) Abbreviations EGF, epidermal growth factor NGF, nerve growth factor TGF-a, transforming growth factor-a and at an early stage it w as suggested that it participates in the regulation of fetal dev elopment (6 , 7)_ Most results concerning a possible ph ysiologic role for EGF have been obtained by injecti on of pharmacologic dos es of the peptide. Because EGF is sy nthesized in several org ans and is believed to act locally, it is impossible to induce EGF defici enc y by surgery . A different approa ch is to induce an immunologic EGF deficiency. Thi s techniqu e was introduced by Gorin and Johnson (8), who immunized rats with mou se NGF and show ed that the offspring had the predicted developmental defects, whereas the adult immunized rats were unaffected. Concerning EGF, only passive immunization, in a heterologous system, has been used so far.
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For example, the injection of rabbit anti-mouse EGF into newb orn mice resulted in an increased perinatal mortality (9) .
The purpose of the pr esent study was to induce autoimmunity against rat E GF, describe the induced ant ib odies, and describe possible effects of the autoim munity against EGF in the adult female rat.
METHODS
Immun ization protocol. Twent y female Wi star rats (Pan: W ist) age d 10 -11 wk were immunized by intraderm al inj ection of 1 nmol of rat EGF in complete Freund's adjuva nt. Th is was fo llowed by three booster injec tio ns at an interv al of 14 d. For booster injections, 0.5 nmo l of rat EGF in complete Fre und 's adjuva nt was used (8) . T wo control gro ups we re used . In one gro up, the rats we re immunized with ph ysiologic sali ne and Freund ' s complete adj uva nt according to the same sc heme , and in the last gro up the rats were not immunized. Six rabbi ts were immunized accordin g to the sa me sc heme, except that a dose of 10 nmol of rat EG F was used for the first immunization and a dose of 10 nmol of EGF and Freund's incomplete adjuva nt for booster injection s.
Observations. During the imm uniza tion period, the rats were ob served for signs of illness or failure to thrive. Another gro up of rats we re w eighed weekly during the immunization per iod . To ev aluate the amounts of EG F excreted in the urine, the animals we re placed in metabolic cages and their urin e co llec ted for 24 h. Urinary creatinine was assessed by the Jaffe meth od with an SMAC (Simu lta neo us Multiple An alyzer wit h Com puter) (Technico n Instru ments, Tarrytow n, NY) , and urinary EG F was qu antifi ed by RIA (10) .
Antibodies. Ten d after the third and the fo urth immunization , 400 ILL of blood from eac h rat were collected from the tail. Th e blood was allowed to clot and thereafter cen trifuge d for 10 min at 1500 X g. Th e ability to bind 6-kD EGF purified fro m rat subma ndib ular glands and 45-kD EGF purifi ed from rat uri ne was determ ined by incuba tion of 100 f1L [~20 000 cpm (~40 fmo l)] of 125I-EGF (6 kD or 45 kD) with 100 ILL of rat se rum in dilution (1:10, 1:100, 1:100 0 and 1:100 00) ove rnig ht. Free and bound tracers were separated by polyethylene glycol (11) . Th e unbound fract ion was assessed in a y-countcr (R iacountcr, Melsgaurd Medical, Hersholrn, Denmark). Onl y antis era obtained after the fou rth immunization, whieh at a dilution of I: 10 bound more than 60 % o f added labeled EG F, were used for further analyses.
RIA for rat liGF. Th e RIA for rat EO F that uses rabbit anti-rat EO F (H13) has previou sly been described ( 10) . To characterize the rat anti-ra t EG F antibodies, we per formed RIA analyses in wh ich the rabbit anti-rat EOP ser um was replace d by rat anti-rat EGF se rum. EGF pur ified from the submandibular g lands was used as labeled pepti de and ca libra tor (0 -4.H pmol /ml.). Th e follow ing sa mples were examined: rat sa liva [1.7 pm ol EO P/ mL (de term ined by RIA using rabbit anti-rat EO P ( 10)], rat urine [2.5 pmol EGP/ mL (determined by RIA)], and rat TO P-a [10 pmol /ml, (co nce ntratio n supplied by the manufacturer) I (Peninsula, Me rseys ide, UK). From the ca libration curves, Sca tchard plots were constructed, and the affinity co nsta nt and the number o f bind ing sites we re estimated (12) .
In vitro receptor binding of liGF antibody complexes.
Rad iorc ccptor assay was per form ed as previou sly describ ed ( 13) . In brief, antiserum or no nimrnunc ser um (100 ILL, dilut ed I: 10) wa s incubated with 100 ILL o f 125 1_EG F I~20 000 cp m (~40 fmol)]. After 2 h at room temp erature, 100 ILL (I mg protein/mL) of human placenta membranes were added and the incu bation was continued ov ernight. Th e receptor-bound complexes we re separa ted from unbound antibody-EGF co mp lexes by filtra tion throu gh 0.2-/Lm filters (SM 11107 Sartorius, Gottinge n, Germ any). Fil ters (cont aining the receptor-b oun d fraction) we re counted in a v-counter. For determination of the maxim al binding of labeled EGF to the memb ran es, the immun e serum was rep lace d by PBA [0.1 M phosph ate buffer, 0.1 % human albumin (Be hringwerke , Marburg, Germ any), pH 8.0], and for determination of non specific binding of labeled EGF to the filters, the placenta membranes we re repl aced by PBA. Th e nonspecific binding of the tracer to the filters was below 2.5 %, and the maximal binding of EGF to the membranes wa s 65 % (55-67%) .
Metabolism of EGF antibody complexes. A S -200
Seph acryl column (1.0 X 45 em) (Pharmacia, Uppsala, Sw eden) was packed according to the manufacturer's instructions. Th e column was calibrated w ith De xtran Blue (Pharmacia), hum an albumin (Behringw erke), 12SI_EGF (6 kD), and 22Na CI (Amersham, Buckingham shir e, UK).
12SI_EGF (20 X 10
6 cpm) wa s prein cubated for 3 h with 100
ILL of rat anti-rat EG F, applied to the S-200 Seph acryl column, and run in 0.9% NaCI at a flow rate of 0.8 mL/2.5 min. Al l 12SI_EGF eluted in one peak near the vo id vo lume , ind icating that all the lab eled EGF wa s bound to rat anti-rat EG F. Th e peak fractions we re pooled .
In vivo metabolism was studied as previ ously described (14) \""\ J1I .;")l."U..'U;")lIv;");") 1ll",;il W I",;i vll 1I1 v I( l;,) l II Vv :-'dIlIIJl\;;). 1"'\)1 \,.;UIlI P i:lI l ;) \JII , a co ntro l group (/I = 6) received an injection of 1251 _EG F, and blo od samples were drawn after 1,2,3,5, 10, and 15 min . The sa mples were counted in a y-countcr and the 24-h samp les we re run on the S-200 Scphacry l co lumn as described above to exa mine w hether the radioacti vit y repr esented antibod y-bound EG F.
RGF. S ix-k D EGF was purified from rat subm and ibul ar g lands as previou sly described. Th e pe ptide was pure as judged from S DS polyacr ylarnid ge ls ( 10) . Fort y-five-kD EG F from rat urin e was pur ified as described ( I I). 125l_EG F wa s prepared by the ehloramine-T meth od (sp act, 450-500 cpm /frn ol EGF ), as describ ed elsew here ( 14) .
Histologic examinations. T issue fro m adult rats was fixed by im mersion. Bonin ' s fixat ive w ithout ace tic ac id was used. Th e tissues we re posu ixcd in 70 % ethano l and embedded in paraffin. T he su bma nd ibular g lands, the lungs, the kidneys, the sma ll intestine, the liver , and the spleen we re invest igated . Histolog ic sec tio ns we re sta ined with peri odic aci d-Sc hiff, hem atox ylin , and aura ntia and exa mined indep end entl y by two investigators .
Immunohistochemistry. Five-u rn sections from the subma ndi bular glands, the lungs , the kidneys, and the duodenum were investigated. Antisera raised in rabbits against 6-kD EGF purified from rat subm andibular g lands (ab 3(23) or purified 0.2 from human urine [ab 1589 (15) ] were used. The immunoreaction was visualized by the peroxidas e-antiperoxidase technique according to Sternberger (16) . The sections were slightly counterstained with hematoxylin and examined independently by two investigators.
Calculations . Results are expressed as median with range in parentheses , unless other wise stated . For comp arison of groups, the Mann-Whitn ey U test was used. For comparison of the development of titers after the third and fourth immunizations, the Wilcoxon-Pratt test for paired data were used. The program " Ligand" was used for estimation of the apparent affinity constant and the concentration of binding sites (17) . Of the 20 rats immunized with rat EGF, 15 developed antibodi es, which at a dilution of 1:10 were able to bind greater than 60% of exogenous iodinated EGF, after the fourth immunization (Fig. 1) . None of the sera from control-immunized rats bound 125I_EGF. The titers were significantly better after four immunizations than after three (p < 0.003). In addition to the binding of 6-kD EGF, the antibodies also bound 45-kD EGF purified from rat urine (Fig. 2) . All of six rabbits immunized four times with rat EGF produced antibodies.
The apparent affinity constant toward 6-kD EGF purified from the submandibular glands was estimated for antiserum from 15 rats and six rabbits using Scatchard plots (Table 1) . Scatchard plots that indicated two classes of binding sites were obtained for serum from nine rats. None of the Scatchard plots for rabbit sera indicated two classes of binding sites. The Data are given as median, with range in parentheses. For nine of the rats, a second class of binding sites was indicated by the Scatchard plots. Figure 1 . Binding of rat EGF by rat anti-rat EGF. The dilution of rat antisera that bound 50% of added labeled rat EGF (titer) after the third and fourth immunizations. The titer was significantly higher after the fourth immunization. y axis: titer, logarithmic scale. apparent affinity constant and the number of binding sites are shown in Figure 3 and summarized in Table 1 .
The antisera recognized endogenous EGF present in saliva and urine in a comparable although not identical manner (Fig. 4) . TGF-a at a concentration of 10 pmol/mL was measured as < 0.3 pmol/mL.
To assess whether antibody-bound EGF could bind to the EGF receptor, 1251_EGF was preincubat ed with the antisera before receptor binding . This caused a median of 97% (90-98%) inhibition of the receptor binding in vitro for the rat antisera and a median of 91% (85-96%) inhibition for the rabbit sera.
To study the biologic significance of the antibodies, we comp ared the disappearance of iodinated EGF and iodinated EGF attached to rat anti-EGF in the rat. Although iodinated EGF disappears from the circulation within minutes, more than 40% of the label is stilI present after 4 h if iodinated EGF is bound to the antibody (Fig. 5) . Upon gel chromatography of the 24-h samples from a rat injected with EGF bound to anti-EGF, the radioactivity eluted near the void volume, indicating that the tracer was still antibody bound (data not shown).
The histologic examination of tissues from the immuniz ed animals did not reveal any signs of inflammation or other abnormalities in the organs that produce EGF, i.e. the submandibular glands, the kidneys, the Brunner 's glands of the duodenum, and the lungs. Neither did the liver, which is rich in EGF receptors, show any abnormalities. . EGF in rat saliva and urine, determined by RIA that uses rat anti-EGF antibodi es (rat, II = 15) and rabbit antibodies (rabbit, n = 6). Labeled peptide and calibrator were prepared from rat submandibular glands. Figure 5 . Disappearance of antibody-bound 1251-EGF (0) (n = 4) and free ' 25I_EGF (+) (n = 6) from blood after i.v. injection. x axis: time from injection of the radioactivity. y axis: cpm present in 0.2 mL of blood .
Immunohistochemical localization of EGF and the staining intensity were similar in tissues from immunized rats and control rats. The EGF immunized animals had, during the immunization period, the same growth rate as the rats immunized with saline and Freund's adjuvant [median weight gain in percent of initial weight: 27% (n = 5) versus 21% (n = 4);
Urine samples from the rats immunized with EGF and nonimmunize d rats showed no difference in 24-h urine output 
DISCUSSION
To establish an experimental cond ition of EGF deficiency, we hav e investigated the possibility of inducing auto antibodies against EGF. The immunization protocol we used gave rise to production of EGF antibodies in the majority of the rats immunized with EGF. With respect to affinity constant , the rat antisera were comparable to EGF antib odies induced in rabbit s, whereas the con centration of the high-affinity binding sites was approximately 10 times lower in the rats.
Alth ough there were minor variations in the specificity of the antibodies from individu al rats and rabbits , all antisera recognized pur ified 6-kD rat submandibular EGF, 45-kD rat urinary EGF, and end ogenous EGF present in saliv a and urine. Thi s indicate s two things. First, the antibodies do not recognize the aminoterminal sequence of 6-kD EGF, becau se this sequence is blocked in 45-kD EGF, and second, the rat antibo dies will react w ith end ogenous EGF provided EGF and the antibodies are present in the sam e compartment. It is therefore worth noting th at the urinary ex cretion of EGF is unchanged in the immunized animals. This add s to the increasing amount of ev idence indicating that all urinary EGF is pr oduced in the kidneys and excreted dir ectl y into the urine. Should a significant part of the urin ary EGF be der iv ed from the ci rculatio n, one would expect a decrease in the output of urinary EGF, inasmuch as EGF in the circulation is likel y to attach to the ant ibod ies and therefore not be filtered into the unne.
Binding of EGF to antibodies almost totall y abolished the bind ing of EGF to its recep tor in vitro. Tha t is, we expected the antibody-bound EGF to be inacti vated . This was furth er substantiated by the in vivo experiment. The antibody-bound EGF was present in the circul ation substantially longer than free EGF. In other wor ds, antibody-bound EGF is not bound to its cellular recepto rs as is free EGF. The results indicate that any supposed endocrine or paracrin e effect of EGF is likel y to be affected by the presence of autoantibodies against EGF .
We did not observ e any major changes in the immunized animals concern ing gro wth rate, histologic appearance of EGFprod ucing tissue s, and immun ohistochemical localization of EGF. We believe that two assumptions can be made from these results. First, in the health y adul t rat, circulatory EGF is absen t or unimportant. This is in accord with our previous inability to detect EGF in rat plasma (18) . Second, the EGF-producing cells do not prese nt EGF as a membrane-bound mole cule toward an interstitial fluid that contains anti-EGF.
Gene knockouts are another way to obt ain growth factor deficiency. Animals with EGF gene knockouts have not been reported, but recentl y a gene knockout has been publi shed for TGF-a , another peptid e that acts via the EGF receptor. Mice with TGF-a null mutations showe d only minor abnormalities in the hair follicles and the eyes during development. In agr eement with our EGF receptor hypostimulation , no major effects were observed in the adult mice (19, 20) .
Our findings of no major effects on the adult autoimmune rat are in accor d with comp arable stud ies with NGF (8, 21) . Gorin and Johnson (8) were unable to find effects of autoimmunity toward NGF .
In contrast to results obtained in adult animals , several authors have described striking effects of antibodies to growth factors in the fetus and the newborn animal. The use of antibodies to inactivate growth factors was introduced by Levi-Montalcini and Ang eletti (22) . The y inject ed rabbit antimouse NGF into newborn animals and showed a striking action on the symp athetic gang lia. Later, Gorin and Johnson (8) introduced active immunization. The y immunized rats with mouse NGF and obtained antibodies that cross-reacted with rat NGF. The immun ized animals were unaffec ted, whereas the offspr ing, as expected, were seriously affected. It has been shown that antibodies are transferred to the rat fetus during the last part of pregn ancy and to the suckling rat by way of the milk (23) . Concerning EGF, Tsutsumi and Oka (9) have shown that injecti on of rabbit anti-mou se EGF into pregnant mice caus ed increased perinatal mortality. Bereseth (24) and Green et al. (25) have used addition of rabbit anti-EGF to milk and shown a delayed maturation of the digestive tract.
In conclusion, we have developed autoimmunity against EGF in the rat. In the light of work performed with NGF, we beli eve that this autoimmune model will be useful for the study of a possible physiologic role for EGF in the fetus.
